Asthma is a chronic inflammatory disease of the airways characterized by reversible airway obstruction, Inflammation and hyper responsiveness of the airways. It is characterized by recurrent episodes of wheezing, breathlessness, chest tightness and cough particularly at night / or in the early morning. It currently affects approximately 300 million people world-wide. It is very well described in Unani literature under headings of  Rabu, Buhar, Zeequn-Nafas, Dama and Intesabun-Nafas. Unani physicians treated this disease by Unani medicines up to some extent. Sharbat-e-Sadar which is a Unani pharmacopoeial preparation, is one of the drugs which have been used in Unani system of medicine for the desired purpose but its use as a bronchodilator drug is not yet proved scientifically. Therefore, an open label study was designed to evaluate the efficacy of said Unani formulation scientifically on various research parameters like dose of drug, efficacy and any adverse effect of drug. A total of 30 cases diagnosed with the shortness of breath due to Bronchial Asthma were studied and received the test drug for 90 days. The drug was found safe on hematological and biochemical parameters. The study demonstrated that the test drug is safe and effective in improving the signs & symptoms associated with Bronchial Asthma.